<乌鸦传媒 class="page_title">Metabolic Dysfunction-Associated Steatohepatitis (MASH)
<乌鸦传媒>
A large, well-phenotyped cohort study assessed patients with MASLD to determine if this risk group is undergoing adequate surveillance.
video
<乌鸦传媒 class="article_title">
MASLD Risk Stratification: What Role for ECG?
<乌鸦传媒 class="article_title">
Fatty Liver Disease and Heavy Alcohol Use: A Bad Combination
Korean researchers recently analyzed rates of alcohol consumption and their effect on liver-related mortality risk in roughly 1 million people who were, or were not, diagnosed with metabolic dysfunction-associated fatty liver disease.
video
<乌鸦传媒 class="article_title">
MASLD and Cardiac Abnormalities
video
<乌鸦传媒 class="article_title">
Screening for MASH: What Are the Noninvasive Methods?
video
<乌鸦传媒 class="article_title">
MASLD in Diabetes: What Clinicians Should Know
"There is a significant interplay between type 2 diabetes and MASLD," explains Sobia Laique, MD, of Cleveland Clinic. Thorough screening is important to identify at-risk MASH in patients with diabetes.(3:23)
video
<乌鸦传媒 class="article_title">
MASLD Nomenclature: Why the Change?
<乌鸦传媒 class="article_title">
Lean MASH Patients Face Higher Mortality and Worse Outcomes
These data confirm that lean patients with MASH may be at greater risk of poor health outcomes than non-lean patients with MASH.
<乌鸦传媒 class="article_title">
MASLD Clinical Outcomes: Numerous, Dangerous
Data on clinical outcomes in MASLD are lacking. This study鈥檚 goal was to provide a comprehensive meta-analysis of the longitudinal outcomes associated with MASLD.
<乌鸦传媒 class="article_title">
In MASLD, Which Serum Lipid-Soluble Micronutrients Heighten Risk?
Serum lipid-soluble micronutrients, such as 25(OH)D and carotenoids, may be protective in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), whereas tocopherols may be associated with pathology, according to this report.
<乌鸦传媒 class="article_title">
Q&A: Christos S. Mantzoros, MD, PhD, Discusses Steatotic Liver Disease
Christos S. Mantzoros, MD, DSc, PhD, professor of medicine at Harvard Medical School and Boston University, answers our questions about changes in the way we approach steatotic liver disease, formerly known as fatty liver disease.
<乌鸦传媒 class="article_title">
Screening For MASH: How Accurate Are Non-Invasive Tests?
Investigators reported on the clinical utility of several non-invasive screening methods to reduce the burden of invasive liver tissue sampling in patients at risk of MASH.
Patients over age 50 with type 2 diabetes are at particular risk for metabolic dysfunction-associated steatohepatitis, according to the results of this study.
<乌鸦传媒 class="article_title">
MASLD in Lean Patients: What do We Know?
This systematic review of the literature provides an interpretation of the new criteria related to lean MASLD.